Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US

2Firsts Events by 2FIRSTS, edited by Sophia Lv
Aug.19.2024
Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
Accorto CEO Tom Beaudet and CSO Dr. Vince Angelico visit 2FIRSTS HQ for in-depth discussion on US e-cigarette industry.

On August 19, Tom Beaudet, CEO of the U.S. compliance company Accorto, and Dr. Vince Angelico, CSO (Chief Scientific Officer), visited the headquarters of 2FIRSTS to have a detailed discussion with Alan Zhao, co-founder and CEO of 2FIRSTS. Both sides explored the high-quality development of the e-cigarette industry in the American market.

 

Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
Tom (third from the right), Vincent (fourth from the right), Alan Zhao (second from the right), and 2FIRSTS staff members posing for a photo. | Image source: 2FIRSTS

 

During the meeting, Alan Zhao warmly welcomed the arrival of the Accorto delegation and expressed appreciation for their professional insights in the field of PMTA compliance. Alan Zhao stated that with the U.S. Food and Drug Administration (FDA) continuously strengthening its regulation and enforcement of the e-cigarette market, compliance in the e-cigarette industry has become a crucial issue that companies cannot afford to overlook. In the face of market changes, companies must pay close attention to compliance services in order to ensure their sustainable and steady development.

 

Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
2024 Global New Tobacco Regulations Report" produced by 2FIRSTS|Image source: 2FIRSTS

 

In order to deepen mutual understanding and cooperation, Alan Zhao on behalf of 2FIRSTS presented Tom with the "2024 Global New Tobacco Regulation Report" (English version) produced by 2FIRSTS. The report provides a comprehensive analysis of the current global regulation of novel tobacco products and their development trends, offering valuable insights and guidance to the industry.

 

Tom highly praised 2FIRSTS' professionalism and contribution to the industry's development, and stated that he looks forward to deeper collaboration with 2FIRSTS in the e-cigarette compliance field in the future. Accorto, as a leading provider of PMTA compliance services, has been dedicated to assisting e-cigarette companies in FDA reviews to ensure products can legally enter the US market.

 

This exchange not only deepened mutual understanding between both parties, but also laid a solid foundation for future cooperation. 2FIRSTS and Accorto have both expressed their commitment to working together to promote the healthy and orderly development of the e-cigarette industry, providing global consumers with safer and more compliant e-cigarette products.

 

As a key media and research institution in the e-cigarette industry, 2FIRSTS will continue to leverage its influence within the industry to promote information exchange and knowledge sharing. We will work with partners like Accorto to contribute to the high-quality development of the e-cigarette industry.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
China's Ministry of Finance and State Taxation Administration announced on October 12, 2026, that value-added tax (VAT) export rebates for vape devices, nicotine and its salts, and certain non-combustible inhalation products will be eliminated from April 1, 2027. The measure adds four tobacco- and nicotine-related customs codes, including 8543400010, which covers vape devices and qualifying empty pods. China previously eliminated rebates for nicotine-containing vaping products and devices under code 8543400090 in April 2026. According to industry classification information held by 2Firsts, the latter currently corresponds to heated tobacco devices. Export excise tax refund and exemption arrangements will remain unchanged.
Special Report
Oct.12
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01